Loyal raises $100M Series C led by age1 and The Longevity Fund to finish LOY-002 regulatory work and prepare launch

Loyal/LOY-002

Loyal raised a $100M Series C led by age1 and The Longevity Fund to advance LOY-002 toward FDA Expanded Conditional Approval, expand operations and prepare for commercial launch of its canine longevity therapy.

• LOY-002 is designed to extend healthy lifespan in senior dogs; pivotal STAY trial is fully enrolled with >1,300 dogs across 70+ clinics.
• FDA has accepted safety and efficacy sections; manufacturing review remains before conditional approval.
• Round includes age1 and The Longevity Fund; proceeds fund regulatory completion, team expansion and commercial readiness.